U.S., May 22 -- ClinicalTrials.gov registry received information related to the study (NCT06982040) titled 'Evaluate the Efficacy and Safety of NTQ5082 Capsules in Patients With Primary IgA Nephropathy' on May 12.
Brief Summary: NTQ5082 is a small molecule inhibitor of complement factor B (CFB) that inhibits the enzymatic activity of CFB, thereby blocking the alternative pathway of the complement activation cascade. It is being clinically developed for the treatment of primary IgA nephropathy The main objectives of the study were to assess the efficacy and safety of NTQ5082 capsules in the treatment of patients with primary IgA nephropathy.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Primary IgA Nephropathy
Inter...